At this time, I'd like to turn the conference over to Atabak Mokari. Today, we issued three press releases, one announcing the positive outcome of our 178 patients Phase 2 trial of relacorilant in combination with nab-paclitaxel to treat patients with platinum-resistant ovarian cancer. Second, announcing markedly decreased liver fat in patients in our Phase 2 trial of miricorilant as a potential treatment for nonalcoholic steatohepatitis or NASH, and the third, providing a clinical update and announcing our financial results for the first quarter.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting